At 19.4% CAGR, the Europe Direct-to-Consumer Genetic Testing Market is Projected to be Worth US$ 2,103.66 million by 2030, Says Business Market Insights

According to Business Market Insights' research, the Europe Direct-to-Consumer genetic testing market was valued at US$ 507.98 in 2022 and is expected to reach US$ 2,103.66 million by 2030, registering a CAGR of 19.4% from 2022 to 2030. Growing incidence of genetic disorders, increasing awareness about potential benefits of genetic testing, and growing adoption of Single Nucleotide Polymorphism (SNP) chips are among the critical factors attributed to the Europe Direct-to-Consumer genetic testing market expansion. 

There has been a steady paradigm shift from traditional medicine to personalized medicine with increasing scientific knowledge in recent years. This shift is due to advances in genetic engineering, single nucleotide polymorphism (SNP) genotyping, and the high adoption of microarrays and biochip technologies. The introduction of genetic microarray analysis platforms with hundreds of thousands of SNPs will encourage the implementation of advanced algorithms to test for more secluded genealogical relationships more openly between individuals. In addition, the demand for detecting malignant tumors has also increased. In the pediatric field, the short turnaround time without the need to hybridize SNP variations to massive deletions has led to enormous demand. As a result, the market is expected to grow as more genetic abnormalities are detected and treated.

SNP chips with high efficiency and accuracy are witnessing an increase in demand due to the constant need for technologically advanced and more sophisticated DTC genetic testing. A high preference for SNP chips can be attributed to their ability to measure dosage changes and DNA polymorphism, along with various applications such as the SNP microarray analysis that are vital for cancer research. Furthermore, an increasing need to minimize errors in DTC genetic testing is expected to drive the adoption of SNP technology, thereby providing an opportunity for the market growth.

On the contrary, high cost and privacy concerns associated with Direct-to-Consumer genetic testing hamper the growth Europe Direct-to-Consumer genetic testing market .

Based on test type, the Europe Direct-to-Consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing segment held 64.2% share of the Europe Direct-to-Consumer genetic testing market in 2022, amassing US$ 326.37 million. It is projected to garner US$ 1,310.55 million by 2030 to expand at 19.0% CAGR during 2022-2030.

By technology, the Europe Direct-to-Consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held 68.7% share of Europe Direct-to-Consumer genetic testing market in 2022, amassing US$ 348.92 million. It is projected to garner US$ 1,483.46 million by 2030 to expand at 19.8% CAGR during 2022-2030.

Based on distribution channel, the Europe Direct-to-Consumer genetic testing market is bifurcated into online and offline. The online segment held 65.7% share of Europe Direct-to-Consumer genetic testing market in 2022, amassing US$ 333.69 million. It is projected to garner US$ 1,399.39 million by 2030 to expand at 19.6% CAGR during 2022-2030.

Based on country, the Europe Direct-to-Consumer genetic testing market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany held 26.6% share of Europe Direct-to-Consumer genetic testing market in 2022, amassing US$ 135.09 million. It is projected to garner US$ 574.01 million by 2030 to expand at 19.8% CAGR during 2022-2030.

Key players operating in the Europe Direct-to-Consumer genetic testing market are Ancestry Genomics Inc, Myriad Genetics, Inc., Living DNA Ltd, 23andMe Inc, and Genetic Technologies Ltd, among others.

- In September 2023: 23andMe Holding Co. and the Sickle Cell 101, have joined forces to expand awareness of people's sickle cell carrier status. The collaboration will include DNA testing and access to 23andMe's Health + Ancestry Service for up to 1,000 eligible participants, and 23andMe will be providing monetary support to Sickle Cell 101 to support this effort.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com